Search Within

Raajit Kumar Rampal

Formats
  1. Meeting Abstract (182)
  2. Journal Article (122)
  3. Review (19)
  4. Research Letter (10)
  5. Book Section (2)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Adult Leukemia (338)
  2. Center for Hematologic Malignancies (338)
  3. Department of Medicine (338)
  4. Hematologic Malignancies, Division of (338)
  5. GSK Faculty (135)
  6. Executive Committee, Center for Hematologic Malignancies (131)

More Groups

People
  1. Ross Levine (87)
  2. Omar Abdel-Wahab (64)
  3. Martin Tallman (41)
  4. Eli Diamond (34)
  5. Ahmet Dogan (30)
  6. Minal Patel (29)

More People

Years
  1. 2025 (10)
  2. 2024 (27)
  3. 2023 (42)
  4. 2022 (36)
  5. 2021 (36)
  6. 2020 (26)

More Years

Publications
  1. Blood (139)
  2. Journal of Clinical Oncology (17)
  3. Blood Advances (15)
  4. Clinical Lymphoma, Myeloma and Leukemia (15)
  5. Haematologica (13)
  6. British Journal of Haematology (10)

More Publications

Publishers
  1. American Society of Hematology (155)
  2. Elsevier Inc. (24)
  3. Nature Publishing Group (21)
  4. American Society of Clinical Oncology (17)
  5. Ferrata Storti Foundation (13)
  6. American Association for Cancer Research (12)

More Publishers

Results (338)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis
    Review

    Bewersdorf, J. P.; Sheth, A. H.; Vetsa, S.; Grimshaw, A.; Giri, S.; Podoltsev, N. A.; Gowda, L.; Tamari, R.; Tallman, M. S.; Rampal, R. K.; more...
    Transplantation and Cellular Therapy (2021)

    Fulltext@MSK | Save
  • Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
    Journal Article

    Navitski, A.; Al-Rawi, D. H.; Liu, Y.; Rubinstein, M. M.; Friedman, C. F.; Rampal, R. K.; Mandelker, D. L.; Cadoo, K.; O'Cearbhaill, R. E.
    Gynecologic Oncology Reports (2021)

    Fulltext@MSK | Save
  • Pelabresib (CPI-0610) improved anemia associated with myelofibrosis: Interim results from the ongoing MANIFEST phase 2 study
    Meeting Abstract

    Bose, P.; Verstovsek, S.; Kremyanskaya, M.; Mascarenhas, J.; Talpaz, M.; Harrison, C.; Rampal, R.; Patriarca, A.; Gupta, V.; Granacher, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Clinical benefit of pelabresib (CPI-0610) in combination with ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis patients: Interim efficacy subgroup analysis from Arm 3 of the MANIFEST phase 2 study
    Meeting Abstract

    Gupta, V.; Kremyanskaya, M.; Mascarenhas, J.; Palandri, F.; Patriarca, A.; Devos, T.; Harrison, C.; Passamonti, F.; Rampal, R.; Mead, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • The BET inhibitor pelabresib decreases inflammatory cytokines, improves bone marrow fibrosis and function, and demonstrates clinical response irrespective of mutation status in myelofibrosis patients in the phase 2 MANIFEST trial
    Meeting Abstract

    Zavidij, O.; Keller, P.; Cui, J. K.; Mertz, J.; Salama, M.; Olteanu, H.; Chiu, A.; Chen, D.; Hanson, C. A.; Chen, Z. H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Add-on parsaclisib (a PI3K5 inhibitor) in patients with myelofibrosis and suboptimal response to ruxolitinib: Interim analysis from a phase 2 study
    Meeting Abstract

    Yacoub, A.; Borate, U.; Rampal, R.; Ali, H.; Wang, E.; Gerds, A.; Hobbs, G.; Kremyanskaya, M.; Winton, E.; O'Connell, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis
    Meeting Abstract

    Yacoub, A.; Wang, E. S.; Rampal, R. K.; Borate, U.; Kremyanskaya, M.; Ali, H.; Hobbs, G. S.; O'Connell, C.; Assad, A.; Erickson-Viitanen, S.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • HMGA1: An epigenetic switch required for MPN progression by inducing GATA-2 and cell cycle progression through enhancer rewiring
    Meeting Abstract

    Li, L.; Kim, J. H.; Lu, W.; Williams, D. M.; Xian, L.; Kim, J.; Rogers, O.; Rampal, R. K.; Koche, R. P.; Cope, L.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Clinical benefit of pelabresib (CPI-0610) in combination with ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis patients: Interim efficacy subgroup analysis from Arm 3 of the MANIFEST phase 2 study
    Meeting Abstract

    Gupta, V.; Kremyanskaya, M.; Mascarenhas, J.; Palandri, F.; Patriarca, A.; Devos, T.; Harrison, C.; Passamonti, F.; Rampal, R.; Mead, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Interferon alpha therapy in essential thrombocythemia and polycythemia vera — A systematic review and meta-analysis
    Journal Article

    Bewersdorf, J. P.; Giri, S.; Wang, R.; Podoltsev, N.; Williams, R. T.; Tallman, M. S.; Rampal, R. K.; Zeidan, A. M.; Stahl, M.
    Leukemia (2021)

    Fulltext@MSK | Save